Journal
EUROPEAN JOURNAL OF NEUROLOGY
Volume 29, Issue 3, Pages 790-801Publisher
WILEY
DOI: 10.1111/ene.15171
Keywords
disease activity; disease-modifying therapies; multiple sclerosis; ocrelizumab; relapsing-remitting multiple sclerosis
Categories
Funding
- F. Hoffmann-La Roche Ltd (Basel, Switzerland)
- F. Hoffmann-La Roche Ltd.
Ask authors/readers for more resources
The study showed that patients with relapsing-remitting multiple sclerosis receiving ocrelizumab treatment achieved a high rate of no evidence of disease activity (NEDA) over 96 weeks, especially for those primarily enrolled based on MRI activity. Patients with lower baseline EDSS scores and those receiving only one prior DMT treatment demonstrated higher rates of NEDA.
Background and purpose Using the treatment goal of no evidence of disease activity (NEDA) incorporating magnetic resonance imaging (MRI) re-baselining, we aimed to assess the efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis with a prior suboptimal response, defined by MRI or relapse criteria, to one or two disease-modifying therapies (DMTs). Methods CASTING was a prospective, international, multicenter, single-arm, open-label phase 3 trial (NCT02861014). Patients (Expanded Disability Status Scale [EDSS] score <= 4.0, with discontinued prior DMT of >= 6 months duration due to suboptimal disease control) received intravenous ocrelizumab 600 mg every 24 weeks for 96 weeks. The primary endpoint was NEDA (defined as absence of relapses, disability progression, and inflammatory MRI measures, with prespecified MRI re-baselining at Week 8) over 96 weeks. Results A total of 680 patients were enrolled, 167 (24.6%) based on MRI activity only. At Week 96, 74.8% (95% confidence interval [CI] 71.3-78.0, n/N = 492/658) of patients had NEDA. NEDA was highest among patients enrolled due to MRI activity alone (80.6% [95% CI 68.6-89.6], n/N = 50/62) versus those enrolled for relapse (75.1% [95% CI 69.0-80.6], n/N = 172/229) or for relapse with MRI (70.5% [95% CI 60.0-79.0], n/N = 74/105). NEDA across subgroups was highest in patients with a baseline EDSS score <2.5 (77.2% [95% CI 72.8-81.2], n/N = 315/408). NEDA was higher in patients receiving one prior DMT (77.6% [95% CI 73.2-81.6], n/N = 312/402) versus two prior DMTs (70.3% [95% CI 64.3-75.8], n/N = 180/256). Conclusions In patients switching therapy due to suboptimal disease control, treatment with ocrelizumab led to an overall high NEDA rate across a wide range of disease-related and demographic subgroups, regardless of prior treatment background, with no new safety signals detected.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available